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Abstract: Celiac disease (CD) is an immune-mediated enteropathy triggered by exposure to 
wheat gluten and similar proteins found in rye and barley that affects genetically susceptible 
persons. This immune-mediated enteropathy is characterized by villous atrophy, intraepithelial 
lymphocytosis, and crypt hyperplasia. Once thought a disease that largely presented with 
malnourished children, the wide spectrum of disease activity is now better recognized and this 
has resulted in a shift in the presenting symptoms of most patients with CD. New advances in 
testing, both serologic and endoscopic, have dramatically increased the detection and diagnosis 
of CD. While the gluten-free diet is still the only treatment for CD, recent investigations have 
explored alternative approaches, including the use of altered nonimmunogenic wheat variants, 
enzymatic degradation of gluten, tissue transglutaminase inhibitors, induction of tolerance, and 
peptides to restore integrity to intestinal tight junctions.
Keywords: immune-mediated enteropathy, gliadin, gluten, epidemiology, CD diagnosis, 
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Epidemiology
Until the 1970s, the estimated global prevalence of celiac disease (CD) in the general 
population was just 0.03%.1 This estimate was based on rates of clinically detected 
CD and for a long time it was felt that CD was rare in many Western populations with 
increased frequency in places such as the west of Ireland. Subsequently it became 
apparent that the rate of CD diagnosis was increasing and most assumed that it was 
due to greater detection due to use of serology linked to heightened suspicion.2 The 
true prevalence is difficult to determine since there is a wide spectrum of symptoms 
associated with the disease.3 The iceberg model of disease has been frequently applied 
to CD in that the tip of the iceberg represents patients with classic malabsorption, 
while the more atypical presentations represent the portion of the iceberg that is 
invisible, but much larger, below the waterline.4 It is estimated that there may be eight 
times as many subclinical and silent celiac cases as there are classically symptomatic 
cases.5 The ratio between diagnosed and undiagnosed cases may be even greater. In 
a population-based study, the seroprevalence of undiagnosed CD in patients aged 
50 years or older was 0.8%.6
The real prevalence of CD, based largely on serological screening in the general 
populations of North America and Western Europe, is estimated to be between 0.5% 
and 1.26%, with a somewhat higher prevalence in the Scandinavian countries, Ireland, 
and the UK (where it was estimated to be between 1.0% and 1.5%).3Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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While most studies have been based on seroprevalence, 
one recent study confirmed high prevalence with parallel 
  serology and histopathology in a population-based study. These 
patients had no symptoms or reasons to suspect that they had 
CD. When including patients with positive   serology, increased 
intraepithelial lymphocytes (IELs) without atrophy, and two 
previously treated patients, the prevalence was 1.8%.7
This increase in prevalence is not solely due to more 
effective diagnostic methods. Recent studies from the USA 
and Europe have shown a 2–4.5-fold increase in the preva-
lence of CD.4,8,9 One study showed a fourfold increase, 
comparing sera obtained from young men in the 1950s 
with present-day sera from cohorts of men with similar 
ages at testing and similar birth years.6 This increase in 
prevalence in both age cohorts suggests the presence of 
pervasive environmental factor(s) that are triggering the 
development of CD in genetically susceptible individuals 
of any age. A more recent study showed increased preva-
lence in the same cohort of adults followed over 25 years.8 
There are many possible environmental factors that could be 
responsible, including changes in the timing of introduction, 
quality, quantity, or processing of cereal. In the last 40 years, 
there have been many changes in wheat genetics, bread pro-
cessing, and enzymatic modifications of wheat prolamins. A 
more general explanation could be the “hygiene hypothesis,” 
referring to changing patterns of early childhood infections, 
which has also been suggested as a possible catalyst in the 
changing prevalence of CD4 but is unlikely to explain the 
new occurrence of disease in the elderly.
Pathophysiology
Gluten is a mixture of proteins (including gliadins and 
glutenins) that are found in wheat grains. Similar proteins 
from barley (hordeins) and rye (secalins) also induce injury.10 
Of these, the gliadin peptides are the most immunogenic for 
CD. These peptides resist complete digestion and likely pass 
across the intestinal epithelial barrier via both transcellular 
and paracellular mechanisms. Transcellular mechanisms 
include IFN-γ stimulated transcytosis via intracellular 
vesicles.11 Paracellular mechanisms of peptide are thought 
to occur via increased intestinal permeability via so-called 
entry “leaky” tight junctions.
One of the proteins involved in controlling tight junctions 
is zonulin. When gliadin binds to CXCR3 chemokine receptor, 
zonulin is released from intestinal cells. Ex vivo studies have 
shown that increased levels of zonulin lead to decreased 
transepithelial electrical resistance (TEER). In vivo studies 
in mice demonstrated that zonulin increased both gastric 
and small intestinal permeability. The mechanism by which 
zonulin achieves these changes in TEER and gut permeability 
is via activation of proteinase-activating receptor 2 (PAR2), 
which in turn activates epidermal growth factor receptor 
(EGFR). Activation of EGFR induces an EGFR-driven 
decrease in TEER. Expression of zonulin mRNA is increased 
in individuals with active CD, suggesting that this protein is 
related to intestinal damage in patients with CD.12
Gliadin peptides then stimulate intestinal CD4+ T cells 
in the lamina propria, although there is significant variability 
among epitopes of gliadin in the severity of their indi-
vidual immunogenic responses. The α-gliadin epitopes are 
recognized by T cells in nearly all patients with CD, while 
the γ-gliadin and glutenin epitopes are not as universally 
recognized.10
These epitopes on gliadin are predominantly Gln- and 
Pro-rich peptides that undergo deamidation of select 
glutamine residues by tissue transglutaminase (TTG).10,13,14 
Deamidation involves conversion of neutral glutamine 
residues to negatively charged glutamic acid residues.15 
This process results in significantly increased affinity to 
HLA-DQ2, and in some cases to HLA-DQ8 molecules, and 
leads to an enhanced antigenic presentation of gliadin.1,14–16 
These HLA Class II molecules are expressed on antigen-
presenting cells (ie, macrophages, dendritic cells, and 
B cells). Binding of deamidated peptides activates gluten-
specific CD4+ T-helper 1 (Th1) cells in the lamina propria, 
which in turn results in intraepithelial lymphocytosis, crypt 
hyperplasia, production of cytokines leading to villous 
atrophy, and expansion of B cells that produce antibodies to 
gliadin and TTG.15,17 While TTG IgA and IgG antibodies are 
associated with the development of CD, it is not clear whether 
they have a pathogenic role. Anti-TTG2 IgA deposits are 
detected in morphologically normal jejunum before systemic 
detection of TTG antibody, which suggests a pathogenic role 
for antibodies.18
Role of genetics in the development 
of CD
The HLA molecules DQ2 and, to a lesser degree, DQ8, are 
intrinsic to the development of CD, playing a major role in 
the risk of disease development, as well as disease severity. 
HLA-DQ2 is found in 95% of patients with CD and is 
encoded by the gene pairs DQA1*05/DQB1*02xx. The 
alternative HLADQ2.2 molecule, encoded by DQA1*0201/
DQB1*0202, is only rarely associated with CD risk though 
rare cases occur. Approximately 5%–10% of patients with 
CD carry HLA-DQ8 (encoded by HLA-DQA1*0301 and Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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HLA-DQB1*0302). These heterodimers are thought to be 
responsible for at least 40% of disease heritability.1,19 The 
remaining 60% is thought to be due to a number of non-
HLA genes.19
While HLA-DQ2 and HLA-DQ8 are found in virtually 
all patients with CD, it is important to note that 30%–35% 
of Caucasians carry these markers, of whom only 2%–5% 
will develop CD. This disparity and the less than 100% 
concordance in monozygous twins suggest both other 
genetic and environmental factors are required for the 
development of CD.17 Genome-wide association studies on 
CD have identified non-HLA loci that are also associated 
with increased risk of developing CD. Many of these non-
HLA loci are found in other autoimmune diseases.19 These 
loci include genes that encode for proteins such as integrins 
(encoded by ITGA4 at 2q31); chemokines, cytokines, and 
their receptors (IL2 and IL21 at 4q27, IL18RAP at 2q11–
2q12, IL12A at 3q25–3q26, the CCR1 and CCR3 cluster 
locus at 3p21); several proteins associated with signaling 
pathways (RGS1 at 1q31, SH2B3 at 12q24, ATXN2 at 
12q24, TNFAIP at 6q23.3, REL at 2p16.1); proteins involved 
in B-cell (RGS1) and T-cell activation (TAGAP at 6q25); 
and proteins involved in cell adhesion and motility (LPP at 
3q28).1 Single nucleotide polymorphisms on chromosome 
2q31 are also associated with CD susceptibility.20 Of these 
non-HLA loci, the 4q27 region, which hosts IL2 and IL21, 
shows the strongest association to the development of CD, 
yet it accounts for less than 1% of genetic risk.1,20 Even when 
combining all known non-HLA loci, they attribute for less 
than 10% of genetic risk.1
Role of environmental factors in the 
development of CD
Environmental factors that contribute to the development 
of CD in genetically susceptible individuals include early 
and substantial exposure of infants to dietary gluten, early 
infection with enteropathic viruses, and changes in bacterial 
flora of the gut.17 The contribution of infant feeding has 
been debated since the 1980s and this subsequently led to 
the recommendation that small amounts of gluten should 
be gradually introduced between 4 and 7 months of age 
during concomitant breastfeeding.1,21 Children exposed to 
gluten in the first 3 months of life have a 5× increased risk 
of CD compared with children exposed to gluten at between 
4 and 6 months of age. Children exposed to gluten after 
7 months have a marginally increased risk of developing 
CD in comparison with those exposed at 4–6 months.22 The 
mechanism by which breast milk exerts its protective effect 
against the development of CD is unknown, but it is theorized 
that breast milk may have immune-modulating properties that 
suppress T cells, dilute the amount of ingested gluten, prevent 
gastrointestinal (GI) infections that would increase intestinal 
permeability and gluten exposure, or decrease gliadan uptake 
because IgA antibodies in breast milk agglutinate with 
gliadin.21 Infectious etiologies have been proposed to have a 
causal relationship with the development of CD in genetically 
susceptible individuals. These include adenovirus type 12, 
HCV , Campylobacter jejuni, Giardia lamblia, enterovirus, 
and rotavirus.1,22
Socioeconomic status may also be a factor in the 
development of CD. An epidemiologic survey comparing 
schoolchildren in a prosperous neighborhood of Finland with 
schoolchildren living in a poorer neighborhood in Russia sug-
gested that lower socioeconomic status may protect against 
CD development.1 It is possible, however, that children in 
poorer neighborhoods may have been breastfed longer for 
financial reasons and that the difference is related to breast 
milk exposure and not strictly socioeconomic status.
Clinical presentation
CD subtype
The subtypes of CD include classical, atypical, latent, and 
silent CD (Table 1). The classical symptoms associated 
with CD are diarrhea, abdominal distension, and failure to 
Table 1 Classification of CD subtypes
Clinical symptoms Serology HLA markers Pathology
Classic CD Diarrhea, abdominal distension, failure  
to thrive, or weight loss
Positive Positive villous atrophy always present
Atypical CD Iron deficiency anemia, osteoporosis,  
short stature, arthritis, infertility, peripheral 
neuropathy, abnormal liver function tests
Positive Positive variable degree of villous atrophy  
is present, more subtle 
microarchitectural changes
Silent CD Asymptomatic Positive Positive villous atrophy
Latent CD vary from asymptomatic to symptoms  
seen in atypical CD
Positive or  
negative
Positive No villous atrophy but cellular 
immune cells antibody infiltration seen
Abbreviations: CD, celiac disease; HLA, human leukocyte antigen.Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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thrive in the setting of villous atrophy.3,23 This triad is more 
commonly seen in individuals between 6 and 24 months of 
age.1,23 Atypical CD is characterized by milder GI symptoms 
similar to irritable bowel syndrome.1,3 It is associated with 
extraintestinal manifestations, such as iron deficiency anemia, 
osteoporosis, short stature, arthritis, infertility, peripheral 
neuropathy, hypertransaminasemia, and even liver failure at 
the time of diagnosis.1,3,17 Latent CD applies to patients who 
carry HLA-DQ2 and/or HLA-DQ8, with or without positive 
serology, and who have not yet developed villous atrophy 
but may have mild inflammation or immune activation may 
be seen.1 Patients in this subset may be asymptomatic or 
may have extraintestinal manifestations.1,24 Silent CD is 
characterized by positive serology and villous atrophy in an 
asymptomatic patient.3 After undertaking a gluten-free diet 
(GFD), some asymptomatic patients will notice improvement 
in different physical and psychological aspects of their 
life, such as improved appetite, reduced fatigue, or fewer 
behavioral abnormalities. In retrospect, these patients are 
perhaps not as asymptomatic as they thought they were prior 
to undertaking a GFD.1
Presentation of CD in children
CD has previously been considered a disease of failure to 
thrive associated with classic symptoms of malabsorption: 
predominately weight loss, steatorrhea, and multiple 
deficiencies, most often presenting in very young children. 
However, several studies have shown that the proportion 
of children presenting with classic symptoms has dropped 
substantially over time. Indeed, most recently, the majority 
of patients now present with non-GI symptoms. The age at 
which children are presenting with CD is also increasing and 
is now approaches a median of 7 years.23,25
CD often presents with failure of axial height development 
and delayed menarche in girls. It can often be found in   family 
members of individuals found to have CD or in children with 
type I diabetes.
Presentation of CD in adults
When diagnosed in adults, the peak is usually in the fourth 
and fifth decade of life for women and men, respectively.1,26 
This latter peak was previously attributed to diagnostic delay, 
although new studies show that CD can develop later in life in 
genetically susceptible individuals – presumably in response 
to external triggers. There has also been greater appreciation 
for the iceberg model of disease and, thus, increased aware-
ness of the heterogeneity of this disease process. Increased 
availability of noninvasive testing, such as antiendomysial 
antibody (EMA), antitransglutaminase antibody (AGA), and 
TTG tests, has also increased the ability to screen patients. It 
is important to note that CD-specific serologic tests such as 
AGA and EMA did not become available until the 1990s.25
As has been seen in children, similar changes in the 
frequency of GI symptoms at the time of diagnosis have 
been observed in the adult population. Prior to 1973, 73% 
of adults presented with diarrhea; in contrast to only 43% 
after 1993.27
who should be considered for testing?
Testing should be considered in all people with malabsorp-
tion, chronic diarrhea, iron deficiency anemia, vitamin D defi-
ciency, osteoporosis, dyspepsia, and unexplained abdominal 
pain. Increased suspicion of CD is warranted in patients with 
atypical presentations of CD or who have one of the follow-
ing conditions that are associated with CD: diabetes mel-
litus type 1, autoimmune hepatitis, autoimmune thyroiditis, 
vitiligo, Addison’s disease, Down’s syndrome, or dermatitis 
herpetiformis.23 A first-degree relative diagnosed with CD 
should also be considered for testing. While the inheritance 
of CD does not follow clear Mendelian inheritance, there 
is clearly a genetic predisposition to development of this 
disease. The prevalence of CD in first-degree relatives is 
estimated to be between 2.8% and 17.2%; in second-degree 
relatives, the prevalence ranges between 2.6% and 19.5%.3
Diagnosis
Several sets of criteria recommend that the diagnosis of CD 
is made when there are typical small-intestinal histopatho-
logical abnormalities and a clinical response to a strict GFD. 
Symptoms should improve within 2 weeks. In asymptomatic 
patients, repeat endoscopy ensuring histopathologic resolu-
tion of disease after a GFD is undertaken would be required to 
fit the diagnostic criteria since these patients lack symptoms 
that can be used as markers of response. The presence of CD-
associated antibodies (ie, TTG, anti-gliadin Ab, endomysial 
Ab, deamidated gliadin Ab) at the time of diagnosis and their 
resolution to normal after a GFD has been undertaken also 
support a diagnosis of CD.1,28
Serology
While antigluten and other less-specific antibodies have been 
in use for many decades, it was only with the development of 
the EMA test in 1983 that the era of modern specific serology 
for CD was ushered in.29 In 1997, tissue transglutaminase 
(TTG) was identified as the actual antigen in the EMA test 
and became the basis for the enzyme-linked immunosorbent Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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assay (ELISA) used today.30 The most sensitive and specific 
serologic tests are EMA IgA and TTG IgA.1 In a systematic 
review of 34 studies, both EMA and TTG had high specificity 
(.99% and .98%, respectively), as well as high sensitivity 
(93% for both). Based on this study, human recombinant 
anti-TTG IgA is the preferred screening test.30
The original antigliadin test has been supplanted by tests 
detecting antibodies against deamidated gliadin peptides.1 
In a meta-analysis of eleven studies, the deamidated gliadin 
peptide (DGP) antibody test was compared to the TTG Ab 
test. The pooled sensitivities for the DGP Ab and TTG 
Ab tests were 87.8% and 93%, respectively. The pooled 
specificities for DGP Ab and TTG Ab were 94.1% and 
96.5%, respectively.15 One of the studies in this meta-analysis 
selected serology from biopsy-proven patients to establish 
the sensitivity, specificity, and accuracy of the DGP antibody 
test. In this patient population, the sensitivity, specificity, and 
accuracy for the different tests were as follows: deamidated 
gliadin-IgA (74%, 95%, 86%), deamidated gliadin-IgG 
(65%, 98%, 84%), and deamidated gliadin-IgA+IgG (75%, 
94%, 86%).31 Based on this meta-analysis, deamidated 
gliadin antibody is a better diagnostic test for CD than gliadin 
antibody testing, but there is insufficient evidence to support 
its use over the TTG or EMA tests.
Based on the current sensitivity and specificity of the 
aforementioned serologic tests, the TTG-IgA test is recom-
mended as the first test to obtain when screening for CD.31 
Initial testing for celiac-specific antibodies at the time of 
diagnosis are crucial, not only to confirm a histologically 
obtained diagnosis, but also to permit a baseline from which 
follow-up can be determined in response to a GFD.
Histology
In the setting of positive serology or a high clinical suspicion 
despite negative serology, the next step in the diagnostic 
process is duodenal biopsy.1,32 Biopsy can be avoided in 
untreated patients with negative serology and in whom 
clinical suspicion is low.1 The spectrum of gluten-sensitive 
enteropathy varies from severe with total villous atrophy and 
crypt hyperplasia, to mild – indeed, only involving increase 
in inflammation in the surface epithelium – so-called intraepi-
thelial lymphocytosis. Several schema have been developed 
to describe the varying degree of injury. The Oberhuber 
modification of the Marsh schema has been used in such a 
fashion (Table 2).1,33,34 Though never the original intention 
of Marsh, it has become a common means of reporting the 
histologic injury related to CD. In general, the greater the 
degree of injury, the more specific the changes are for CD.1,34 
One criticism of using this as a pathologic grading system is 
the decreased interobserver and intraobserver agreement.35
It is not just villous height that can be measured, but 
also villous width, which can be used to assess the degree 
of architectural change, and the combination of villous 
height and villous width can be used to estimate villous 
cross-sectional area and may be better able to judge the 
degree of recovery in patients treated with a GFD.36 The area 
as calculated may be a more sensitive marker of intestinal 
damage. Clearly, while villous height may improve, without 
improvement in width, the total surface area will still remain 
reduced. The mildest degree of injury accessible on standard 
light microscopy is intraepithelial lymphocytosis. This may 
precede the development of mucosal atrophy; however, this 
is a very nonspecific finding and often can be the result of 
nonsteroidal anti-inflammatory drugs, helicobacter infection, 
parasitic infection, or other autoimmune disorders. Only a 
minority of patients who had lymphocytic duodenosis without 
atrophy have this because of gluten-sensitive enteropathy. 
Those subjects can be identified by positive celiac serology 
and the carriage of appropriate HLA risk markers.37,38 Gluten-
sensitive enteropathy may present even more subtly, with a 
histology that appears entirely normal, though IgA deposits 
within the mucosa can be a subtle marker of gluten-sensitivity 
Table 2 Oberhuber/Marsh classification34
Villous architecture Crypt height Intraepithelial  
lymphocytosis/ECa
Diagnostic of CD?
Type 0 Normal Normal height ,40 iEL/100 EC No
Type 1 Normal Normal height .40 iEL/100 EC No
Type 2 Normal Crypt hyperplasia .40 iEL/100 EC No
Type 3A Mild villous flattening increased height .40 iEL/100 EC Yes
Type 3B Marked villous flattening increased height .40 iEL/100 EC Yes
Type 3C Total villous flattening  
(flat mucosa)
increased height .40 iEL/100 EC Yes
Notes: aRecently this threshold was reduced to 25/100;7 the data displayed in this table have been collated from data in Oberhuber.34
Abbreviations: CD, celiac disease; EC, enterocytes.Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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response. This has been described in individuals who have 
circulating antibodies against endomysium or TTG and often 
they have symptoms that will respond to a GFD.1,34
While the presence of villous atrophy is specific for CD, 
there are other diseases also characterized by villous atrophy. 
A list of these diseases is included in Table 3. In the absence 
of other serologic and histologic markers of CD, these condi-
tions should be considered in patients with villous atrophy.
interpretation of serology and histology
Patients with positive serology and histologic changes consistent 
with CD are straightforward diagnoses, as demonstrated in 
 Figure 1. However, patients with positive serology and negative 
biopsies represent a diagnostic dilemma, as they may represent 
false serologic positives, false histologic negatives, early CD,24 
or latent CD.1 When considering the limitations of the serologic 
tests, it is important to note that these tests were created and 
conducted in populations with a higher prevalence of CD; 
therefore, when these tests are performed in populations with 
lower prevalence, the positive predictive power falls and will 
result in an increased number of false-positives. Conversely, 
the negative predictive power will increase as the test is used 
in populations with lower prevalence of CD; provided that 
the sensitivity of the test is .50%. In fact, even quite specific 
tests such as the EMA, TTG IgA, and TTG IgG tests may be 
associated with as high as a 30%–35% false-positive rate when 
used in low-prevalence populations.5
In patients where the clinical suspicion of CD is high 
but serology and/or histology (most commonly due to prior 
treatment with a GFD) are negative, testing for the presence 
of HLA-DQ2 and HLA-DQ8 may identify high-risk patients 
who may benefit from long-term screening.19 These markers 
carry a high negative predictive value and, therefore, if both 
are negative, there is a low likelihood that the patient has CD 
or is at risk for developing CD.1
Some physicians have suggested that in setting of 
strongly positive TTG, endoscopy may not be necessary 
to make a diagnosis of CD. This hypothesis assumes that 
TTG directly correlates with histopathology and is specific 
enough to rule in all stages of pathology. In a study by Vivas 
et al, TTG titers were found to be independent predictors for 
Marsh III lesions in children and adults. However, it was 
noted that adults with CD typically experience less severe 
atrophy and lower TTG antibody titers than children.32 
While strongly positive TTG titers may be sufficient to make 
the diagnosis of CD in children, it may be less attractive to 
use in diagnosing adults where the certainty provided by 
biopsy is easier to obtain.
The most definitive seropathological correlation was 
undertaken in a parallel population-based study of 1000 adults 
in Sweden, where all subjects had biopsies and serology with 
TTG. This study showed that the specificity of TTG is very 
high at over 98%. However, the positive predictive value in 
the context of a setting where the prevalence of CD was 1.6% 
was just 50%. Endomysial antibody positivity substantially 
increased this positive predictive value to virtually 100%. The 
study also established 25 IELs/100 enterocytes as a threshold 
for serologic predetermined gluten sensitivity. Even in this 
most rigorous setting, it is important to consider duodenal 
biopsy in the diagnosis of CD in adults, though a combination 
of positive TTG followed by a positive endomysial antibody 
had a combined specificity of virtually 100%.7 As such, it is 
not advisable to forego duodenal biopsy in the diagnosis of 
CD in adults since disease presentation and monitoring in 
adults differs greatly from children.
Standard endoscopy
Current standard of care is to take at least four to six biopsy 
specimens from the descending duodenum and bulbar 
mucosa.40–43 The purpose of multiple blind biopsies is to 
increase the diagnostic yield and avoid false negatives 
associated with patchy forms of CD.42,44 False negatives 
can also be obtained as a result of poor sampling quality, 
tangential sectioning, or failure to orient tissue correctly 
after biopsy.33
Table 3 Differential diagnosis of villous atrophy39
• Celiac disease
• Tropical sprue
• Adult-onset autoimmune enteropathy
• Hypogammaglobulinemia
• idiopathic AiDS enteropathy
• Food protein hypersensitivity
• Eosinophilic gastroenteritis
• whipple disease
• Abetalipoproteinemia
• intestinal lymphoma
• Collagenous sprue
• Tuberculosis
• Giardiasis
• Crohn’s disease
• Small-bowel bacterial overgrowth
• infectious enteritis
• Parasitic infestation
• Severe malnutrition
• Small-bowel ischemia
Note: Reproduced from: Rubio-Tapia A, Murray JA. Classification and management of 
refractory coeliac disease. Gut. 59:547–557. Copyright notice 2010 with permission 
of BMJ Publishing Group Ltd.39
Abbreviation: AIDS, acquired immune deficiency syndrome.Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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A number of endoscopic signs are associated with CD, 
including: mosaic pattern of the duodenal mucosa, loss of 
duodenal folds, nodular pattern of the bulb and duodenal 
mucosa, scalloping of the valvulae conniventes, and visibility 
of submucosal vessels. These features are neither sensitive 
nor specific enough to be used as screening tools during 
endoscopy.40,42,45,46 Endoscopic clues to villous atrophy may 
also indicate the need for biopsies or also provide direction 
for targeted biopsies.41
Enhanced endoscopy
water-immersion technique
The water-immersion technique (WIT) involves instillation 
of water into the duodenum that raises the duodenal villi 
so they appear as tiny finger-like structures. This can be 
used easily during regular endoscopy and the absence of 
villi could be then an indication for biopsy in patients who 
do not already have an indication for duodenal biopsy. In a 
prospective study of 19 children by Cammarota et al, WIT 
was found to have had 93% accuracy.40,44
Chromoendoscopy
Chromoendoscopy includes topical application of stains or 
pigments to improve tissue localization, characterization, or 
diagnosis during endoscopy. Indigo carmine staining highlights 
villous atrophy; however, it does not improve the ability to 
detect scalloping, loss of folds, or mosaic patterns.47
Altering the light use for imaging with narrow-band 
imaging (NBI) or Fujinon intelligence color enhancement 
(FICE) (Fujinon Inc, Wayne, NJ) may provide enhanced 
images of villi but do not consistently improve pre-CD 
detection in low-risk patients.48
video capsule endoscopy
Video capsule endoscopy provides a method to examine the 
mucosa of the entire small intestine and it has been used to 
confirm the almost universal involvement of the proximal 
intestine with a widely varying extent of atrophy, which can 
vary from a very short length to the entire small intestine with 
a median involvement of 10%. The magnification and motion 
views enhance the detection of atrophy with a sensitivity 
of approximately 90%, which can be improved further 
with advanced image analysis techniques. Video capsule 
endoscopy has also been shown to heal the small intestine, 
but CD heals from the bottom up. It also may be able to detect 
complications in unresponsive CD, and it can be used to 
confirm villous atrophy in those patients unable or unwilling 
to undergo endoscopy.49 Video capsule endoscopy also 
allows for examination of the entire small bowel and there-
fore may be able to detect the presence of CD beyond the 
duodenum.49 Based on video capsule endoscopy studies, the 
mean percentage of small intestine with villous atrophy has 
been reported at between 16.4% and 17.9%.26,50
Our recent study has identified a quantitative method 
that seems to dramatically reduce the false0 positive rate 
of video capsule endoscopy and may be helpful in reducing 
interobserver variance in its interpretation. Other studies 
evaluating the diagnosis of CD using video capsule endoscopy 
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deamidated gliadin
antibody
Positive Negative
Small
bowel
biopsy
CD
unlikely
Check HLA
DQ2 and
HLA DQ8
CD
unlikely
Positive Negative
Small
bowel
biopsy
CD
unlikely
High
clinical
suspicion
Low
clinical
suspicion
Figure 1 Algorithm for the diagnosis of celiac disease.
Note: *Nutritional deficiencies include testing iron, folic acid, calcium, vitamin D, vitamin B12 and vitamin A.
Abbreviations: TTG, tissue transglutaminase; EGD, esophagogastroduodenoscopy; CD, celiac disease; GFD, gluten-free diet.Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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have reported wide ranges in the sensitivity (70%–95.2%) 
and specificity (63.6%–100%).51,52 These ranges may be 
secondary to interobserver differences. One way to overcome 
this limitation involves a quantitative method that calculates 
mean frame-to-frame pixel brightness, image texture, and 
periodicity in brightness to classify and identify patients with 
CD. Use of these quantitative markers results in sensitivity 
of 92.7% and specificity of 93.5%.51
If specific complications are detected by video   capsule 
endoscopy, plans can be made with balloon-assisted 
endoscopy to obtain specific samples for histologic review.
Balloon-assisted endoscopy
Balloon-assisted endoscopy is useful to exclude enteropathy-
associated T-cell lymphoma (EATL), ulcerative jejunitis, 
and small bowel adenocarcinoma. These disease processes 
may be suggested by abnormalities seen during video capsule 
endoscopy (ie, ulcerations, masses, stenosis), signs/symptoms 
suggestive of refractory CD, or radiographic signs of small 
bowel masses or of small bowel stenosis/obstruction.53,54 The 
antegrade approach is the preferred route of insertion of the 
balloon-assisted endoscopy since EATL and ulcerative jeju-
nitis are more common in the jejunum.54,55 EATL typically 
appears endoscopically as multiple ulcers without the presence 
of a definite tumor mass. These ulcers can vary greatly and may 
be circumferential, discrete, or confluent ulcerative lesions that 
can lead to stenosis.55 If a mass is present, it is typically with 
associated necrosis or stenosis.54 Balloon-assisted endoscopy 
should also be used during follow-up of previously treated 
EATL to reassess the effect of surgery/chemotherapy.55
Spirus enteroscopy is another technique that uses a 
corkscrew effect to pull the bowel over the scope to achieve 
deep enteroscopy. Studies on CD are awaited.
Microscale endoscopy
Confocal endomicroscopy with intravenous injection of 
fluorescein may be sufficient to identify villous atrophy 
or crypt hyperplasia33 – a reported sensitivity of 94% 
and specificity was 92%–100%.56 It can detect increased 
intraepithelial lymphocytosis.
Endocytoscopy, visualizing the mucosa with methylene 
blue, had a sensitivity of 88% and specificity of 100%.57 The 
following visual characteristics are significant predictors of 
Marsh III pathology – low number of villi per visual field, 
confluence of villi, irregular epithelial lining, and inability 
to delineated loop capillaries.43 While endocytoscopy 
can identify atrophy, it cannot identify intraepithelial 
lymphocytosis.43,57
Optical coherence tomography combines ultrasound 
and infrared back-scattering light to visualize the mucosa 
and submucosa with a sensitivity and specificity of 82% and 
100%, respectively.46 Like endocytoscopy, optical coherence 
tomography is limited in its inability to assess hypertrophic 
crypts and intraepithelial lymphocyte count.46
Summary
Simple techniques can be applied by any endoscopist and 
should increase the detection of villous atrophy in those in 
whom there is a low suspicion of CD preprocedure. Use of 
the newer techniques is still confined to the highly specialized 
endoscopy centers that could further enhance our ability to 
detect and characterize villous atrophy.
Treatment
The GFD is the standard treatment for patients with CD 
and requires avoidance of wheat, rye, and barley products. 
This diet usually results in clinical, serologic, and histologic 
remission. Unfortunately, it can be a difficult lifestyle 
modification for patients to make given the financial burden of 
gluten-free products, willpower required, and high likelihood 
of “hidden” gluten contamination.1,58 Gluten-free foods by 
definition should not contain more than 20 mg/kg of gluten 
in total.21 This small amount reflects the acceptable level of 
contamination that may occur in food processing or the use 
of wheat starch from which the gluten has been removed. In 
a prospective study using a gluten microchallenge, as little 
as 50 mg per day was sufficient to cause mucosal damage 
after 3 months.58 Levels higher than this threshold may 
frequently contaminate foods that theoretically should be 
gluten free.59 Currently, there is little or no verification of 
levels of gluten contamination even in foods labeled gluten 
free; the regulations in the USA have been promulgated to 
address this important issue.
Ingestion of oats is generally safe; even ingestions of 
large quantities of oats in patients with CD in remission do 
not result in changes in histology, EMA antibody titers, or 
symptoms. It is important to note that antibodies to avenin, 
an oat prolamin, have been detected in children and adults 
with untreated CD. These antibodies likely represent 
increased food antigen exposure as demonstrated by the 
fact that these avenin antibodies decrease after initiation 
of a GFD and they are not present in patients who ingest 
oats after remission of their CD.60 Rarely, patients with 
CD may react to the sparse immunogenic peptide motifs in 
oats.61 Commercial varieties of oats are often contaminated 
with wheat or other gluten-containing grains; therefore, Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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especially grown and tested varieties are necessary for 
the diet.
Micronutrient deficiencies are common. It is equally 
important to consider that the adoption of a GFD may result 
in a nutritionally unbalanced diet with poor intake of valuable 
micronutrients. Vitamin B supplementation with B12, folate, 
and B6 may result in normalized plasma total homocysteine 
(a marker of vitamin B status) and improvements in well-
being – specifically, reduced anxiety and depression. Zinc and 
copper deficiencies can occur in CD and result in significant 
sequelae.62
In patients where the diagnosis is not certain (ie, patients 
with positive serology and nondiagnostic biopsies), it is 
unclear whether these patients should adopt a GFD. In a 
study by Kurppa et al, patients with positive EMA serology, 
HLA-type requisite, and either Marsh I or Marsh II were 
randomized to gluten-free and unrestricted diets.24 After 
1 year, EMA titers, intraepithelial lymphocytosis, small 
bowel mucosal morphology, and symptoms improved 
in patients on a GFD, whereas those who continued an 
unrestricted diet had no improvement in these markers of 
disease activity and experienced progression of small bowel 
mucosal morphology. They otherwise did not experience 
worsening serologic markers.24 Some may argue that it is not 
prudent to wait for villous atrophy to develop since there may 
be complications that may not be reversible (ie, osteoporosis, 
dental enamel defects, and growth retardation).
While it has been held in the past that there was little 
evidence to support the detection of or the treatment of 
asymptomatic CD, recent work from several centers has 
suggested that patients with supposedly asymptomatic disease 
are not asymptomatic after they have been, in retrospect, 
quite symptomatic on follow-up. In addition, asymptomatic 
disease in diagnosed CD may be associated with an increased 
mortality, though this theory remains controversial.4 There is 
little doubt that even asymptomatic disease can be associated 
with significant consequences; for example, for bone health 
there are conflicting reports on the benefits that a GFD can 
affect fracture rate, though bone density may improve in 
many patients on a strict GFD.63 There is probably less 
benefit to be obtained from screening and identifying CD in 
elderly individuals who have no symptoms as their long-term 
potential for developing symptoms may be limited because 
of their age, whereas younger individuals would have the 
most benefit from having CD identified and treated.6 With 
respect to fracture risk, there is conflicting evidence about 
whether a GFD in an asymptomatic patient with CD would 
abrogate increased fracture risk.5 This is an important point 
to note, since fracture risk is frequently given as one of the 
key reasons for undertaking a strict GFD.
Adherence to a gluten-free diet: assessing 
compliance and recognizing obstacles
Lifelong adherence to a GFD is central to the treatment of 
this disease. Most patients will respond symptomatically 
to a reduction or elimination of gluten from their diet.64 
While strict adherence to a GFD may be achievable for 
some, many patients have incomplete adherence.65 Several 
factors can affect adherence – appropriate education and 
counseling, family and social support, and psychological 
factors. Contamination of the GFD may occur because of 
deliberate and intentional ingestion of gluten, insufficient 
information of gluten content of foods, and contamination 
in the processing and preparation of foods. Food prepared 
in restaurants or outside the home provides the opportunity 
for gluten contamination and may be beyond the patient’s 
direct control.
Adherence to a GFD can be assessed by a face-to-face 
consultation with a registered dietician with expertise in the 
GFD and by serology.66 Typically, 6 months after the diag-
nosis the serologic levels should have dropped significantly 
and should continue to show a downward trajectory and 
by 1–2 years after exclusion from the diet, serology should 
become negative. However, a negative serology does not 
necessarily guarantee that the small intestine has healed.67
Alternatively, a positive serology, suggests that intestinal 
damage will have persisted and that there is likely gluten 
contamination in the diet. Finally, follow-up biopsies often 
reveal failure to heal, and the most common reason for this 
is likely some degree of gluten contamination.68
Novel therapeutic approaches
A patient who adheres to a GFD could easily ingest a 
significant amount of gluten beyond safe thresholds, given 
the allowance of 20 mg/kg of gluten in “gluten-free food.” 
New treatment modalities focus on modification of dietary 
food products, enzymatic degradation or binding of gluten 
to decrease the degree of gluten exposure, inhibition of 
small intestinal permeability, blocking the deamination of 
gluten via inhibition of TTG, and modulation of the immune 
system.1,69,71
Modification of dietary food products
Consideration has been given to “detoxifying” wheat to 
remove or scramble the toxic peptides of gluten. This 
approach is problematic since wheat gluten proteins account Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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for the continuous viscoelastic network in dough, thereby 
determining the dough’s strength and baking properties. 
Similar challenges have been found when attempting to select 
grains with low or absent immunogenic sequences.69
Enzymatic degradation of gluten: the 
“glutenase” approach
Endopeptidases (aka glutenases) aim to degrade gluten by 
targeting the proline-rich peptides which otherwise resist the 
body’s natural proteases and contain highly immunogenic 
peptides. This degradation would hopefully also destroy the 
epitopes, thereby preventing gluten’s usual immunogenic 
response in patients with CD.10,70 These glutenases are 
designed to serve as adjuvant therapy to prevent harm from 
incidental low-level gluten exposure during a GFD.70
Prolyl endopeptidases (PEPs) are glutenases that are 
ingested with a meal and become activated in the upper 
intestine where they work with pancreatic and brush border 
membrane proteases.10,14 Gluten is composed of many differ-
ent gliadin and glutenin polypeptides. Approximately 60% 
of the gliadin proteins are α-gliadin, 30% are γ-gliadins, 
and 10% are ω-gliadins. An in vitro study has demonstrated 
that treatment of gluten with PEPs results in degradation of 
gluten to smaller peptides which decrease T-cell activation 
and replication in patients with CD.10 In an in vitro study by 
Marti et al, Flavobacterium meningosepticum PEP treatment 
led to elimination of all α-gliadin epitope–bearing peptides 
and some decrease of γ-gliadins epitopes.10 In an in vivo 
double-blind crossover study by Pyle et al, patients who 
developed fat or carbohydrate malabsorption after a 2-week 
gluten challenge experienced decreased malabsorption after 
administration of PEP.14
ALV003 is a combination of two glutenases – a cysteine 
endoprotease derived from germinating barley seeds in 
addition to a PEP from Sphingomonas capsulate. In a study 
by Tye-Din et al, ALV003 was given to HLA-DQ2 CD 
patients as part of a gluten challenge study.70 ALV003 was 
effective in decreasing gluten-specific T-cell responses, as 
identified via enzyme-linked immunospot assay (ELISpot). 
Further studies are underway to study the effect on clinically-
relevant outcomes.
Some limitations of endopeptidase therapy are that it 
requires a sufficient amount of enzyme to be ingested and 
also requires sufficient exposure of gliadin to the enzyme 
to ensure adequate degradation.21 Copolymer binders of 
gluten sequences have also been studied experimentally as a 
potential means of treating CD. Studies in gluten-sensitized 
mice have demonstrated that this can effectively reduce the 
immune response consequently as gluten exposure.71 This 
has not yet been studied in humans.
inhibition of small intestinal permeability
Increased intestinal permeability is a constant and perhaps 
early event in CD. Zonulin has been identified as a key 
mediator of gluten-induced permeability changes and is 
increased in CD. This may provide an ideal drug target. 
Increased serum concentrations of zonulin have been detected 
in patients with CD.21 AT-1001 is an octapeptide inhibitor 
of paracellular permeability that inhibits gliadin-induced 
cytoskeleton rearrangement of intestinal epithelial cells, 
tight junction disassembly, and peak F-actin increment. So 
far, it appears that larazotide is safe, generally well tolerated 
by patients, and prevents increased intestinal permeability. 
Further studies are underway to better define the effects of 
this new drug.72
TTG inhibitors
Inhibition of TTG is an attractive therapeutic possibility 
since TTG deamidates gluten, thereby increasing glu-
ten’s immunogenic response, in addition to acting as a 
proinflammatory agent itself. TTG is involved in many 
other biologic pathways, such as apoptosis, cell adhesion, 
signal transduction, collage assembly, and wound repair 
  mechanism. Given its broad range of actions, universal 
inhibition of this molecule could have disastrous results 
and therefore may limit its role as a drug target.69 In mouse 
studies, a dihydroisoazole derivative has shown promise as a 
TTG inhibitor; it has good oral bioavailability, a short serum 
half-life, and has shown effective TTG inhibition in small 
intestinal tissue. Mice tolerated the compound for 2 weeks, 
although there was some suggestion that this compound has 
the potential for hepatotoxicity.73
immune system modulation
Under the hypothesis that the disappearance of intestinal 
parasites from humans in developed countries has created 
a situation where some individuals develop an autoimmune 
disease, some investigators are exploring the role of 
parasites in the treatment of inflammatory bowel disease 
and CD. A randomized double-blind placebo-controlled 
study evaluating immunity and disease activity of patients 
with CD before and after inoculation with the human 
hookworm Necator americanus was recently completed. The 
investigators surmise that reintroduction of this parasite will 
lead to interference with the intestinal immune system, which 
will allow for decreased gluten sensitivity.74Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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Desensitization therapy with  
peptide-based therapeutic vaccination
Nexvax2 (Nexpep, Ivanhoe, Victoria, Australia) is a peptide-
based therapeutic vaccine that has induced immune tolerance 
in rodent models of HLA-DQ2-restricted T-cell immunity to 
gluten. Its safety is being currently investigated in patients 
with treated CD.75
Nonresponsive CD
As many as 10%–20% of patients diagnosed with CD will have 
persistent or recurring symptoms despite adherence to a GFD76 
and there may be many reasons for this. Most commonly, it is 
due to contamination of the diet with gluten. It is also important 
to review the original diagnosis, as the diagnosis of CD may 
have been incorrect, resulting in   failure to respond to a GFD. 
Additional diagnoses occurring in association with CD are 
quite common and include: lactose intolerance, microscopic 
colitis, small intestinal bacterial overgrowth, pancreatic exo-
crine insufficiency, and functional disorders of the gut.77
Complications, most significantly of EATL, may be 
preceded by refractory CD (RCD) with evidence of clonality 
detectable on biopsy. RCD itself is relatively uncommon, even 
among patients with nonresponsive disease.78 Inflammation 
can lead to stricturing in the intestine and substantial motility 
disorders can also occur and cause persistent or recurring 
symptoms.79
The leading cause of nonresponsive CD is persistent 
gluten exposure and this is seen in 30% of patients who 
report persistent symptoms. To assess adherence, current 
practice is to examine the patient’s TTG titers and to have 
the patient evaluated by an expert dietician. While TTG has 
been validated to serve as a marker of diagnosis, its utility as a 
marker of adherence has not been validated. Another dilemma 
with this practice is that many patients do not have access to 
an expert registered dietician. A seven-question standardized 
questionnaire, developed by Leffler et al, incorporates the 
presence of CD-related symptoms, self-efficacy, reasons for 
keeping to a GFD, and perceived adherence to a GFD. This 
questionnaire has a sensitivity of 74%, specificity of 77%, 
positive predictive value of 50%, and a negative predictive 
value of 90% when compared with the methods employed 
by an experienced dietician. This tool could be a used as a 
screening method to identify patients who would benefit from 
a session with an expert dietician.66
If gluten exposure is resolved and symptoms persist, 
other etiologies to consider include: RCD, intestinal T-cell 
lymphoma, small intestinal bacterial overgrowth, disaccharide 
intolerance, irritable bowel syndrome,80 tropical sprue, 
collagenous sprue, adult-onset autoimmune enteropathy, 
hypogammaglobulinemia, and Crohn’s disease.39 Figure 2 
demonstrates an algorithm that can be used as a guide to 
evaluate the patient with nonresponsive CD.
Unresponsive CD?
Verify initial diagnosis
of CD was correct 
•R eview serology
and small bowel 
biopsy pathology
(obtained prior to 
starting GFD)
•P erform HLA typing
CD unlikely; consider
alternate diagnosis 
Refer to dietician to
rule out continued
gluten exposure
EGD with small bowel
biopsy –send for
•H istology
• Flow cytometry
•T CR δ rearrangement to
test for RCD, UJ, EATL
EGD with small bowel
aspirate to rule out
bacterial overgrowth 
Colonoscopy with
random  biopsies to
rule out CC and LC
•R e-educate regarding GFD
•A ssess barriers (ie:
financial, depression,
anxiety, availability, etc)
If all negative
Negative
Not
compliant
Positive
Compliant
Trial of pancreatic
enzyme supplements
Pancreatic
insufficiency
If symptoms improve
with enzyme supplement
Consider other diagnoses (ie: fructose
intolerance, lactose intolerance, IBS,
protein-losing enteropathy, etc)
If no change
Figure 2 Nonresponsive celiac disease algorithm.
Abbreviations: CD, celiac disease; GFD, gluten-free object; HLA, human leukocyte antigen; CC, collagenous colitis; LC, lymphocytic colitis; EGD, esophagogastroduodenoscopy; 
TCR, T-cell receptor; UJ, ulcerative jejunitis; EATL, enteropathy associated T-cell lymphoma; iBS, irritable bowel syndrome.Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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RCD
RCD is defined by persistence or recurrence of clinical and 
histological symptoms despite strict adherence to a GFD 
for at least 6–12 months in the absence of other causes of 
nonresponsive CD.1,39 The incidence per 100,000 person-
years was 0.06 according to the US Caucasian population in 
2000.39 It is more common in patients with adult-onset CD, 
particularly those diagnosed above the age of 50 years,1 and 
is rarely diagnosed in patients under the age of 30.39
RCD should be considered in patients with either new or 
persistent diarrhea, abdominal pain, involuntary weight loss, 
multiple vitamin deficiencies, anemia, fatigue, or malaise. 
Most patients with RCD have normal serology, however, 
others may have persistently positive serology. Reasons for 
persistent positive serology include CD-specific antibodies 
kinetics, upregulation of TTG in response to severe inflamma-
tion or mucosal destruction, as well as coexisting autoimmune 
diseases associated with false-positive CD serology.39
The condition is divided into RCD type I and type II. 
Type I is characterized by an increased but phenotypically 
normal intraepithelial T lymphocytes in the intestinal 
mucosa.1,39,81 Type II is characterized by phenotypically 
aberrant intraepithelial T lymphocytes in the intestinal mucosa. 
Detection of such abnormal lymphocytes is performed on 
either fixed (immunohistochemistry and T-cell receptor 
clonal rearrangement by polymerase chain reaction [PCR]) 
or fresh frozen intestinal tissue (flow cytometry). Abnormal 
lymphocytes are classified based on: (1) loss of normal 
surface markers (CD3, CD4, CD8) is ,50% of those with 
expression of intracytoplasmic CD3 in .50% of intraepithelial 
lymphocytes when evaluating with immunohistochemistry, 
or .20% if using flow cytometry in addition, and (2) T-cell 
receptor chain clonal rearrangements, as detected by PCR.39
Type I and type II RCD have significantly different progno-
ses; type I RCD is typically associated with a 5-year survival of 
80%–96%, while type II is associated with a 44%–58% 5-year 
survival.1,82 Five factors are associated with increased mortal-
ity if present at the time of diagnosis of RCD. These include: 
albumin # 3.2 g/dL, hemoglobin # 11 g/dL, age $ 65 years, 
the presence of aberrant IELs, and total   villous atrophy.82
The difference in prognosis is related to the fact that RCD 
type II has a higher risk of developing lymphoma arising from 
the clonal expansion of aberrant lymphocytes and ultimate 
transformation into EATL.1,81,82 EATL is characterized by 
nonmonomorphic cytomorphology, CD56 negativity, and 
chromosomal gains of 1q and 5q.39 EATL will develop 
within 5 years in 60%–80% of patients diagnosed with RCD 
type II.81 Despite aggressive treatment, the 5-year survival 
rate for EATL is 8%–20%.39 A new, more intensive, regimen 
of chemotherapy has been shown to increase the survival 
rate, but the performance status of many patients may be 
insufficient to prevent such an aggressive regimen.83 EATL 
should be considered in patients with CD who present with 
recurrence of malabsorption, fever, abdominal pain, weight 
loss, and night sweats. EATL can occur throughout the GI 
tract, lungs, ribs, and spleen. When it occurs within the GI 
tract, it has a predilection for the proximal jejunum.1
Patients with type II are also more likely to have 
ulcerative jejunitis, large ulcerations (.1 cm), cavitating 
mesenteric lymph node syndrome, small splenic volume 
(,122 cm3), intussusception, bowel wall thickening, and 
abdominal lymphadenopathy.38
Treatment options for both types of RCD are limited and 
are based on small observational experiences, case reports, and 
expert opinion. The paucity of studies is due to it being a rare 
disease; therefore, it is difficult to recruit enough patients to 
undergo a randomized controlled trial. Treatment options for 
RCD type I include prednisone, budesonide, and combination 
therapy of azathioprine and prednisone.1,39 Patients with RCD 
type II have a variable response to azathioprine, prednisone, 
cyclosporine, infliximab, alemtuzumab, and IL-10 therapy.39,81 
New therapies for RCD type II are being investigated and 
include interleukin-15-blocking antibodies, cladribine, and 
autologous stem cell transplant (ASCT).1 In a small study 
of seven patients by Al-toma et al, patients with RCD type 
II who underwent ASCT had a significant reduction in the 
aberrant T cells in duodenal biopsies and clinical response.81 
This histologic finding was coupled with improvement in 
well-being as well as normalization of hematologic and 
biochemical markers.75
The degree of diarrhea, weight loss, and malnutrition in 
patients with RCD may become severe enough to require 
total parenteral nutrition. Close monitoring and treatment 
of trace mineral deficiencies (ie, copper and zinc) and bone 
density should also be performed. While there is no evidence 
to show that there is benefit to continuing a GFD in patients 
with RCD, strict adherence to a GFD is still widely recom-
mended in all patients with RCD.39
Follow-up
Asymptomatic patients may have persistent villous atrophy 
and therefore carry substantial risk of the complications of 
untreated CD. Biopsy remains the gold standard for assess-
ing histologic response to a GFD. Follow-up practice at 
the authors’ institution is repeat serology in 6 months and 
follow-up endoscopy in 1–2.5 years.Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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The purpose of following histology after initiation of a 
GFD is to assess for mucosal recovery; patients with per-
sistent mucosal damage may have a higher risk of all-cause 
mortality in comparison with patients whose mucosa returns 
to normal.67 These patients with persistent mucosal damage 
despite resolution of symptoms may represent a “latent form 
of RCD” given their increased mortality.39
In a cohort of 241 adults who underwent diagnostic and 
follow-up biopsy, the rate of confirmed mucosal recovery at 
2 years following diagnosis was 34% and was only 66% after 
5 years. This is in contrast with recovery in children, where up 
to 95% of patients diagnosed during childhood will experience 
complete mucosal recovery within 2 years of starting a GFD. 
Clinical response was documented in 82% of patients; however 
it was not a reliable marker of recovery. There was a trend 
associated with mucosal recovery and reduced rate of all-cause 
mortality, although statistical significance was not achieved.68
Prognosis
Clinically diagnosed but untreated CD can result in sub-
stantial morbidity and mortality, because of complications 
including malabsorption, increased risk of malignancies, and, 
in young individuals, suicide. The excess mortality in those 
who have been clinically diagnosed is probably modest and 
varies between a standardized mortality ratio (1.2–2) when 
all ages are included.84
However, the hazard ratio for mortality in some younger 
individuals may actually be higher than that; in one Swedish 
study it was . 6× the expected rate. However, thankfully, the 
absolute rate of mortality is still low. As a matter of concern, 
individuals diagnosed with CD at a young age appear to have 
an increased risk of death by suicide.85
While mortality estimates in diagnosed and presumably 
treated CD are reasonably consistent, that is not the case for 
undiagnosed and untreated CD. In a study of young adults 
(mean age 20.5 years) with undiagnosed CD, there was nearly 
a fourfold increased risk of death during a 45-year follow-up.86 
A study from Finland examined patients (mean age 50 years) 
with undiagnosed CD but did not find such a dramatically 
increased risk of death; however, this population still had an 
increased risk of lymphoma and esophageal cancer.87 A recent 
nested case-control study from the USA compared sero-
logically defined subjects with CD with age- and sex-matched 
sero-negative controls (all patients were age $ 50 years) and 
reported that this population of patients were more likely to have 
osteoporosis, hypothyroidism, lower body mass index, lower 
cholesterol, and lower ferritin. They did not appear to have 
any increased mortality compared with the control subjects.6 
It appears that there may also be an age-dependent excess in 
mortality, though it is also possible that decades of untreated 
CD are necessary for a substantial excess of mortality to occur. 
Further studies encompassing many decades of follow-up in 
individuals where CD has been retrospectively established are 
unlikely to be translated to a prospective, randomized evaluation 
of intervention with a GFD of sufficient duration to capture an 
effect on survival. Hence, it is the young individuals in whom 
CD can be detected long before consequences have occurred 
who are probably most likely to develop negative consequences 
of disease if followed for decades. Individuals of an advanced 
stage may have insufficient life expectancy to accrue such 
an increased risk.6 Complex issues of competing mortality 
and potential benefits of undiagnosed CD in the face of other 
population risks, such as obesity and hypercholesterolemia, 
will need to be considered.
Conclusion
While there have been a number of advances in the understand-
ing of the genetic susceptibility, pathogenesis, and adverse 
outcomes associated with CD, there are still many avenues 
of investigation. Further advances in diagnosis are needed to 
identify sufficiently specific and sensitive serologic markers so 
that the need for endoscopy may be eliminated. In the interim, 
advances in endoscopy will continue to find new ways to exam-
ine in vivo histology, leading to increased diagnostic yield of 
biopsies, and potentially eliminating the need for biopsies. While 
there are no promising cures at this time, there are a number 
of potential therapies that may help protect against accidental 
gluten ingestion and its subsequent immunogenic response.
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